Patent ID: 9551034
Date: 2017-01-24
CPC Classifications: C12Q,G01N,G06N,G16B,G16H

Claim:
1. A method for determining a likelihood of recurrence of renal cell carcinoma for a human patient comprising: (a) measuring, in a renal cell carcinoma sample obtained from the human patient a level of an RNA transcript of PPAP2B, wherein the measuring is performed using polymerase chain reaction (PCR) with a polynucleotide comprising the sequence of SEQ ID NO: 545 and a polynucleotide comprising the sequence of SEQ ID NO: 1277 as PCR primers and a polynucleotide comprising the sequence of SEQ ID NO: 2009 as a probe to detect PPAP2B polynucleotides produced by PCR; (b) normalizing the level of the RNA transcript of PPAP2B against at least one reference RNA transcript from the sample to obtain a normalized PPAP2B expression level; (c) comparing the normalized PPAP2B expression level to a normalized PPAP2B expression level obtained from a renal cell carcinoma sample from a human patient with recurrent renal cell carcinoma; and (d) determining a decreased likelihood for recurrence of renal cell carcinoma for the human patient if the normalized PPAP2B expression level is increased compared to the normalized PPAP2B expression level obtained from the renal cancer sample from the human patient with recurrent renal cell carcinoma.